医学临床研究
  2025年4月6日 星期日           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2018, Vol. 35 Issue (11): 2124-2126    DOI: 10.3969/j.issn.1671-7171.2018.11.015
  论 著 本期目录 | 过刊浏览 | 高级检索 |
男性痛风合并高尿酸血症患者炎症因子、肾功能变化及非布司他治疗效果分析
李永刚
涟水县人民医院肾内科,黑龙江 涟水 223400
Changes of Inflammatory Factors and Renal Function with Febuxostat Treatment in Male Patients of Gout Complicated with Hyperuricemia
LI Yong-gang
Department of Nephrology, Lianshui People's Hospital, Heilongjiang, 223400
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨男性痛风合并高尿酸血症(HUA)患者炎症因子、肾功能变化及非布司他治疗的临床效果。【方法】选取2017年4月至2018年5月在本院诊断且符合纳入标准的90例HUA患者,根据是否痛风将其分为痛风组、非痛风组,每组各45例;同时,选取45例同期体检健康者作为对照组。比较三组炎症因子[超敏反应蛋白(hs-CRP)、白细胞介素-6(IL-6)]、肾功能指标[血尿素氮(BUN)、血肌酐(SCr)、血尿酸(SUA)、肾小球滤过率(eGFR)]水平的变化。痛风组给予非布司他治疗,对比其治疗前与治疗3个月后血清hs-CRP、IL-6、BUN、SCr、SUA及eGFR指标变化。【结果】三组患者血清hs-CRP、IL-6、SCr、SUA、eGFR水平差异均具有统计学意义(均P<0.05),但BUN水平差异无显著性(P>0.05);痛风组与对照组SCr、SUA、eGFR水平差异具有统计学意义(P<0.05),而非痛风组与对照组仅SUA水平差异具有显著性(P<0.05)。治疗后,痛风组血清hs-CRP、IL-6、SUA水平较治疗前均明显下降,差异具有统计学意义(P<0.05),但BUN、SCr、eGFR变化并不明显(P>0.05)。【结论】男性痛风合并HUA患者血清hs-CRP、IL-6、SCr、SUA及eGFR水平明显升高;应用非布司他治疗可明显降低SUA水平,临床疗效满意,值得临床推广应用。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
李永刚
关键词 痛风/并发症高尿酸血症/并发症药用制剂    
Abstract:【Objective】To explore the changes of inflammatory factors, renal function and febuxostat treatment in male patients with gout and hyperuricemia (HUA). 【Methods】A total of 90 patients with hyperuricemia who were diagnosed and met the criteria in our hospital were selected from April. 2017 to May. 2018. According to the presence of gout, patients were divided into the gout group(n=45) and the non-gout group(n=45). Meanwhile, a total of 45 healthy volunteers who had physical examinations at the same time period were selected as the healthy control group. The changes of inflammatory factors [Hypersensitivity reaction protein (hs-CRP), Interleukin-6 (IL-6)] and renal function [Blood urea nitrogen (BUN), Serum creatinine (SCr), Blood uric acid (SUA), Glomerular filtration rate(eGFR)] were compared among the three groups. The gout group was treated with febuxostat, and the changes of inflammatory factors and renal function were compared before and after three month treatment. 【Results】Levels of hs-CRP, IL-6, SCr, SUA, and eGFR showed statistically significant difference among three groups(P<0.05). However, there were no significant differences in BUN level(P>0.05). Significant differences in SCr, SUA, and eGFR were shown between the gout group and the control group(P<0.05)and there was significant difference of SUA level between the non-gout group and healthy control group(P<0.05). After treatment, the serum levels of hs-CRP, IL-6 and SUA in the gout group were significantly lower than those before treatment and the differences were statistically significant(P<0.05). However,the changes of BUN, SCr and eGFR were not significantly different (P>0.05). 【Conclusion】The serum levels of hs-CRP, IL-6, SCr, SUA,and eGFR were significantly increased in male patients with gout complicated with hyperuricemia. The application of febuxostat can reduce the level of SUA. The clinical efficacy was satisfactory and it is worthy of clinical promotion.
Key wordsGout/CO    Hyperuricemia/CO    Pharmaceutical Preparations
收稿日期: 2018-10-16     
PACS:  R696.6  
引用本文:   
李永刚. 男性痛风合并高尿酸血症患者炎症因子、肾功能变化及非布司他治疗效果分析[J]. 医学临床研究, 2018, 35(11): 2124-2126.
LI Yong-gang. Changes of Inflammatory Factors and Renal Function with Febuxostat Treatment in Male Patients of Gout Complicated with Hyperuricemia. JOURNAL OF CLINICAL RESEARCH, 2018, 35(11): 2124-2126.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2018.11.015     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2018/V35/I11/2124
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn